Who are the key players in North America Kidney/Renal Function Test Market industry?

Top 5 players in the North America Kidney/Renal Function Test Market include Abbott Laboratories, Siemens Healthineers, F. Hoffmann-La Roche Ltd, Beckman Coulter (Danaher Corporation), and Sysmex Corporation. These companies lead in innovation, diagnostic technologies, and extensive distribution networks, consistently introducing advanced renal testing solutions to meet clinical demands.

Which segment accounted for the largest North America Kidney/Renal Function Test Market share?

The largest market share is held by hospitals and diagnostic laboratories in the applications segment. This is due to the high volume of diagnostic testing, improved infrastructure, and accessibility to advanced renal function tests in these facilities, enabling early disease detection and timely intervention for patients.

What are the factors driving the North America Kidney/Renal Function Test Market?

Key drivers include technological advancements, growing prevalence of kidney disorders, and strategic partnerships. For example, Siemens Healthineers introduced advanced analyzers for accurate kidney function assessment, catering to increased demand for early diagnosis and efficient monitoring, thus driving substantial market growth in the region.

Which type accounted for the largest North America Kidney/Renal Function Test Market share?

The urine tests segment holds the largest share among renal function test types. This dominance is due to non-invasive sample collection, cost-effectiveness, and their widespread use in detecting early kidney problems, chronic conditions, and overall kidney health assessment in primary healthcare settings.

Home Healthcare

North America Kidney/Renal Function Test Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)

Name: North America Kidney/Renal Function Test Market
Brand: Bussiness Insights

North America Kidney/Renal Function Test Market: by Type (Urine Tests, Blood Tests, Imaging Tests, Biopsy, Glomerular Filtration Rate Tests, Creatinine Clearance Tests), Application (Chronic Kidney Disease, Kidney Stones, Urinary Tract Infection, Diabetes, Hypertension, Others), Distribution Channels (Hospitals, Diagnostic Laboratories, Clinics, Homecare, Research Institutes, Others), Technology (Conventional, Rapid Diagnostic, Point-of-Care, Automated, Molecular, Others), Organization Size (Small, Medium, Large) and By North America Historical & Forecast Period (2020-2035) Comprehensive Study 2025

Last Updated: 31-07-2025 | Format: PDF | Report ID:20363

North America Kidney/Renal Function Test Market Outlook (2020-2035)

The North America Kidney/Renal Function Test Market is witnessing robust growth driven by the rising prevalence of chronic kidney disease (CKD), increasing awareness for early diagnosis, and advancements in testing technologies. With the integration of point-of-care and automated testing, the market landscape is rapidly evolving. The expansion of homecare diagnostic options is further propelling market value, backed by investments from leading healthcare organizations and continuous product innovations aimed at enhancing accuracy and efficiency. As healthcare providers focus on better patient management and regulatory support grows, the demand for kidney/renal function tests is expected to increase steadily across the region.

Latest Market Dynamics

Key Drivers

Rising prevalence of chronic kidney disease and diabetes across the North American population, fueling the need for early and routine kidney function diagnostics. For example, Abbott Laboratories launched an advanced blood test analyzer in Q4 2024 for better accuracy in CKD detection.

Growth of point-of-care testing solutions for kidney function, enabling faster and more convenient diagnostics outside traditional laboratory settings. Nova Biomedical expanded its renal function product line in early 2025 to enhance patient access to quick screening.
Increased partnerships between healthcare providers and diagnostic labs to improve CKD screening outreach. Beckman Coulter announced a major lab integration program with leading hospital systems in January 2025 to streamline test delivery.

Expansion of home-based diagnostic solutions catering to elderly and at-risk populations. Companies like Quest Diagnostics have invested in telehealth-driven renal screening kits, debuting in late 2024.
Introduction of AI and machine learning solutions for early detection and personalized kidney disease management. F. Hoffmann-La Roche Ltd integrated AI-powered analytics in its 2025 renal function portfolio expansion.

High cost associated with molecular diagnostics and limited reimbursement policies restrict widespread adoption, particularly in underinsured markets. Thermo Fisher Scientific continues to face cost challenges in scaling its advanced test technologies.
Data privacy and interoperability issues in integrating patient results across multi-provider healthcare networks. Laboratory Corporation of America Holdings highlighted ongoing integration issues during its Q1 2025 earnings call.

In 2025, urine tests dominate the North American kidney/renal function test market, accounting for nearly half of all diagnostic procedures. Blood tests follow closely due to their integral role in monitoring renal parameters such as creatinine and urea. Imaging tests, though essential for structural assessment, represent a smaller share compared to biochemical analyses. The market reflects a preference for non-invasive, rapid, and repeatable tests that support early detection and routine monitoring of chronic kidney conditions.

Chronic kidney disease (CKD) is the leading application area for renal function testing, commanding over half the market share in 2025. This is due to the increasing incidence of CKD and the need for regular monitoring among diagnosed patients. Kidney stones represent another significant segment, drive by high recurrence rates in the region. Testing for urinary tract infections, though routine, forms a smaller slice of the market as compared to chronic applications, indicative of the broader shift toward proactive disease management.

The North America Kidney/Renal Function Test Market has grown notably over the past few years. From $1,900 million in 2021, the market reached approximately $2,150 million in 2023, driven by increasing CKD and diabetes prevalence. Projections indicate a market size surpassing $3,400 million by 2030 and reaching about $4,200 million by 2035, propelled by technology upgrades and heightened awareness for early diagnosis. Sustained industry partnerships and government health initiatives continue to elevate diagnostic rates, cementing steady revenue escalation for the industry.

Year-over-year growth rates for the North America kidney/renal function test market highlight a dynamic sector. The market recorded a strong 7.2% growth in 2021, which moderated to 6.5% in 2025 as the industry matures, and is forecast to stabilize at 5% by 2030 and 4.3% in 2035. These figures reflect both sustained demand for innovative diagnostics and the impact of increasing market penetration. While the pace of expansion normalizes, the outlook remains promising with steady annual gains expected through the forecast period.

In 2025, the United States commands the majority share of the North America kidney/renal function test market at 78%, reflecting its advanced healthcare infrastructure and high prevalence of chronic kidney disorders. Canada holds 14% of the regional market, supported by substantial government investment in population health management and screening programs. Mexico rounds out the regional split at 8%, signifying untapped growth potential as healthcare accessibility and diagnostic awareness continue to expand.

The market is led by global diagnostics giants. Abbott Laboratories tops the competitive landscape with 19% share, leveraging its extensive test portfolio and distribution network. Siemens Healthineers and Beckman Coulter Inc. follow closely at 16% and 12%, respectively, owing to continual innovation and hospital partnerships. F. Hoffmann-La Roche and Thermo Fisher Scientific together hold 22% of the share as leading innovators. The remainder is distributed among numerous regional and specialized suppliers, reflecting a moderately consolidated market.

Hospitals remain the principal buyers of renal function tests, with a dominant 52% market share in 2025, attributed to comprehensive care provision and in-house laboratory capabilities. Diagnostic laboratories account for 31%, serving both hospitals and independent healthcare providers. Clinics, representing 17%, are gaining traction due to the growing trend toward decentralized diagnostics and outpatient care, with a notable rise in point-of-care and home-based test purchases.

Metrics	Details
Years	2020-2035
Base Year	2025
Market Size	2350
Regions	North America, United States, Canada, Mexico
Segments	By Type (Urine Tests, Blood Tests, Imaging Tests, Biopsy, Glomerular Filtration Rate Tests, Creatinine Clearance Tests), By Application (Chronic Kidney Disease, Kidney Stones, Urinary Tract Infection, Diabetes, Hypertension, Others)
Players	Abbott Laboratories, Siemens Healthineers, Beckman Coulter Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Randox Laboratories, Sysmex Corporation, Nova Biomedical, Arkray Inc., Quest Diagnostics, Laboratory Corporation of America Holdings, Danaher Corporation, Bio-Rad Laboratories Inc., 77 Elektronika Kft., ACON Laboratories, Inc.

April 2025: Siemens Healthineers announces FDA clearance for its new automated renal function analyzer, improving throughput and detection sensitivity.
March 2025: Quest Diagnostics launches at-home kidney health assessment kits across North America, expanding access to early CKD screening.
February 2025: Beckman Coulter Inc. collaborates with major hospital groups in the US to integrate renal function data with electronic health records (EHRs).
January 2025: F. Hoffmann-La Roche Ltd debuts an AI-powered software suite for dialyzed and CKD patient analytics.
July 2024: Abbott Laboratories introduces a next-generation rapid creatinine test approved for both clinical and point-of-care usage.

Key Questions Answered

»What is the market size and growth rate of the global and regional market by various segments?
»What is the market size and growth rate of the market for selective countries?
»Which region or sub-segment is expected to drive the market in the forecast period?
»What factors are estimated to drive and restrain the market growth?
»What are the key technological and market trends shaping the market?
»What are the key opportunities in the market?
»What are the key companies operating in the market?
»Which company accounted for the highest market share?

Why Choose Bussiness Insights?

»Strong Industry Focus
»Extensive Product Offerings
»Customer Research Services
»Robust Research Methodology
»Comprehensive Reports
»Latest Technological Developments
»Value Chain Analysis
»Potential Market Opportunities
»Growth Dynamics
»Quality Assurance
»Post-sales Support
»Regular Report Updates

North America Kidney/Renal Function Test Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)

North America Kidney/Renal Function Test Market Outlook (2020-2035)

Latest Market Dynamics

Key Drivers

Key Trends

Key Opportunities

Key Challenges

Key Restraints

North America Kidney/Renal Function Test Market Share by Type (2025)

North America Kidney/Renal Function Test Market Share by Application (2025)

North America Kidney/Renal Function Test Market Revenue (2020-2035)

North America Kidney/Renal Function Test Market Year-on-Year Growth (2020-2035)

North America Kidney/Renal Function Test Market Share by Region (2025)

North America Kidney/Renal Function Test Market Player Share (2025)

North America Kidney/Renal Function Test Market Buyers Share (2025)

Study Coverage

Key Recent Developments

Frequently asked questions